| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5658143 | Gastroenterology | 2017 | 50 Pages |
Abstract
The immune checkpoint inhibitory molecules PD-1, TIM3, and LAG3 are up-regulated on TAA-specific T cells isolated from human HCC tissues, compared with T cells from tumor-free liver tissues or blood. Antibodies against PD-L1, TIM3, or LAG3 restore responses of HCC-derived T cells to tumor antigens, and combinations of the antibodies have additive effects. Strategies to block PD-L1, TIM3, and LAG3 might be developed for treatment of primary liver cancer.
Keywords
MDCcytotoxic T-lymphocyte associated protein 4TNFTIM3LAG3GPC3BTLACTLA4CFSETregAPCTFLTAAPBMCPD-1MFICTLmRNAPD-L1HCCmessenger RNAtumor-associated antigenantigen-presenting cellsimmunotherapyinterferonIFNTILTumor-infiltrating lymphocytescytotoxic T cellsperipheral blood mononuclear cellsT helper cellsmyeloid dendritic cellsRegulatory T cellsmedian fluorescence intensitytumor necrosis factormajor histocompatibility complexMHCprogrammed cell death 1HBVHCVHepatitis C virushepatitis B virusHepatocellular carcinomacarboxyfluorescein diacetate succinimidyl esterGal-9Glypican 3
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Guoying Zhou, Dave Sprengers, Patrick P.C. Boor, Michail Doukas, Hannah Schutz, Shanta Mancham, Alexander Pedroza-Gonzalez, Wojciech G. Polak, Jeroen de Jonge, Marcia Gaspersz, Haidong Dong, Kris Thielemans, Qiuwei Pan, Jan N.M. IJzermans,